These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27678443)

  • 41. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.
    Sniderman AD; St-Pierre AC; Cantin B; Dagenais GR; Després JP; Lamarche B
    Am J Cardiol; 2003 May; 91(10):1173-7. PubMed ID: 12745098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
    Langlois MR; Chapman MJ; Cobbaert C; Mora S; Remaley AT; Ros E; Watts GF; Borén J; Baum H; Bruckert E; Catapano A; Descamps OS; von Eckardstein A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard BG;
    Clin Chem; 2018 Jul; 64(7):1006-1033. PubMed ID: 29760220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
    Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
    Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
    Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
    Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study.
    Nomikos T; Panagiotakos D; Georgousopoulou E; Metaxa V; Chrysohoou C; Skoumas I; Antonopoulou S; Tousoulis D; Stefanadis C; Pitsavos C;
    Lipids Health Dis; 2015 Sep; 14():108. PubMed ID: 26370413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
    Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH
    Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men.
    Florvall G; Basu S; Larsson A
    J Gerontol A Biol Sci Med Sci; 2006 Dec; 61(12):1262-6. PubMed ID: 17234819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of atherogenic dyslipidaemia in clinical practice guidelines].
    Pedro-Botet J; Mantilla-Morató T; Díaz-Rodríguez Á; Brea-Hernando Á; González-Santos P; Hernández-Mijares A; Pintó X; Millán Núñez-Cortés J
    Clin Investig Arterioscler; 2016; 28(2):65-70. PubMed ID: 26949069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review and meta-analysis of randomized controlled trials of the effect of barley β-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction
    Ho HV; Sievenpiper JL; Zurbau A; Blanco Mejia S; Jovanovski E; Au-Yeung F; Jenkins AL; Vuksan V
    Eur J Clin Nutr; 2016 Nov; 70(11):1239-1245. PubMed ID: 27273067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B.
    Garcia E; Bennett DW; Connelly MA; Jeyarajah EJ; Warf FC; Shalaurova I; Matyus SP; Wolak-Dinsmore J; Oskardmay DN; Young RM; Sampson M; Remaley AT; Otvos JD
    Lipids Health Dis; 2020 Dec; 19(1):247. PubMed ID: 33261644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
    Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
    J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
    Andrikoula M; McDowell IF
    Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical utility of apoB versus LDL-C/non-HDL-C.
    Kohli-Lynch CN; Thanassoulis G; Moran AE; Sniderman AD
    Clin Chim Acta; 2020 Sep; 508():103-108. PubMed ID: 32387091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.
    Holewijn S; den Heijer M; Swinkels DW; Stalenhoef AF; de Graaf J
    J Intern Med; 2010 Dec; 268(6):567-77. PubMed ID: 21091808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levels of lipids and apolipoproteins in three cultures.
    Solhpour A; Parkhideh S; Sarrafzadegan N; Asgary S; Williams K; Jungner I; Aastveit A; Walldius G; Sniderman A
    Atherosclerosis; 2009 Nov; 207(1):200-7. PubMed ID: 19766218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants - An epidemiological perspective.
    Solnica B; Sniderman AD; Wyszomirski A; Rutkowski M; Chlebus K; Bandosz P; Pencina MJ; Zdrojewski T
    Int J Cardiol; 2023 Nov; 390():131150. PubMed ID: 37429441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discordance between non-HDL cholesterol and LDL cholesterol levels in patients with diabetes without previous cardiovascular events.
    Idris I; Al-Ubaidi F
    Diabetes Metab; 2010 Sep; 36(4):299-304. PubMed ID: 20537932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.